18 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26207924	32	Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.	Colorado College
25036789	45	Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.	Swiss Institute of Bioinformatics
24262887	11	Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).	University of Auckland
23122865	24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.	The University of Sydney
22616902	165	Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.	Ludwig Center For Cancer Research of The University of Lausanne
20055453	80	Rational design of indoleamine 2,3-dioxygenase inhibitors.	Institute For Cancer Research
19507862	42	Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.	Incyte
31749906	52	Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy.	Merck
32150677	32	Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to	Universit£
29220788	33	Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.	China Pharmaceutical University
29111717	64	Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.	Iteos Therapeutics